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Emergence of Clostridium difficile NAP1 in Latin America
The NAP1 and NAP2 strains of Clostridium difficile have
been linked to nosocomial outbreaks of antibiotic-associated
diarrhea (AAD) and pseudomembranous colitis in North
American and European countries (4, 5). We found these
strains, together with seven additional pulsed-field gel electro-
phoresis (PFGE) patterns, among 37 isolates recently recov-
ered from patients with AAD in a Costa Rican hospital.
Herein we present the macrorestriction patterns of the isolates
as well as data regarding their toxin genotypes and suscepti-
bility to selected antibiotics.
The isolates were recovered by inoculating a loopful of
diarrheic stool samples onto cefoxitin-cycloserine fructose agar
plates (CCFA; Oxoid). They were identified with the rapid
ID32A system (bioMe´rieux) and a PCR targeting the triose
phosphate isomerase gene (9). We typed the isolates by PFGE
(1) and amplified fragments of the tcdA, tcdB, tcdC, and cdtB
genes by PCR with oligonucleotides and conditions reported
elsewhere (3, 9, 10). These genes code for toxin A, toxin B, the
negative regulator of the pathogenicity locus, and the binding
domain of the binary toxin, respectively. MICs of clindamycin,
metronidazole, vancomycin, moxifloxacin, ciprofloxacin, and
amoxicillin-clavulanate were determined using Etest strips
(AB bioMe´rieux). C. difficile ATCC 700057 and Bacteroides
fragilis ATCC 25285 were used as reference strains. The break-
points recommended by the CLSI (2) and Pela´ez et al. (6) were
used for antimicrobial susceptibility interpretation.
Nine different PFGE types were identified in the collection
(Fig. 1). All isolates were positive for both tcdA and tcdB and
susceptible to vancomycin and metronidazole, which are the
first antibiotics to be prescribed for this type of infection. They
were also susceptible to amoxicillin-clavulanic acid.
More than half the isolates exhibited the macrorestriction pat-
tern of the NAP1 strain (n 20; 54%). All these bacteria had the
gene for the binding domain of the binary toxin and a deletion in
tcdC (Table 1). Only one of the NAP1 strains was susceptible to
clindamycin. In fact, 10 (50%) were categorized as intermediate
and another 9 (45%) as resistant to this antibiotic. One clinda-
mycin-resistant NAP1 strain had a MIC of 256 g ml1. In
FIG. 1. Pulsed-field gel electrophoresis. SmaI dendrogram of 37 isolates of Clostridium difficile recovered from patients with antibiotic-
associated diarrhea in a Costa Rican hospital.
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agreement with recent data (7), all NAP1 isolates were highly
resistant to the two fluoroquinolones tested (Table 1).
The 13 isolates with the SmaI patterns 447, 448, 449, and 452
clustered together (Fig. 1). These 13 isolates lacked the binary
toxin and had a deletion in the tcdC gene (Table 1). In addition,
they were without exception categorized as highly resistant to
clindamycin, moxifloxacin, and ciprofloxacin (Table 1). One strain
with the PFGE pattern 447 and the strains with the PFGE pat-
terns 449 and 452 exhibited the highest MICs to vancomycin
overall.
The isolates with the PFGE patterns 100, 450, and 451
(NAP2) and 247 (NAP9) were negative for the binary toxin
and did not have deletions in the tcdC gene (Table 1). The
strains with the PFGE patterns 100, 450, and 247 (NAP9) were
resistant to clindamycin, moxifloxacin, and ciprofloxacin (Ta-
ble 1). In contrast, the isolate with the PFGE pattern 451
(NAP2) was moderately resistant to clindamycin (MIC  16
g ml1) and highly resistant to ciprofloxacin (MIC  32 g
ml1) but susceptible to moxifloxacin (MIC  2 g ml1).
NAP9 strains have been recently isolated from retail meat (8).
The finding of the NAP1 strain in Latin American countries
is novel and deserves attention from infectious disease special-
ists and epidemiologists to prevent its dissemination.
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TABLE 1. SmaI macrorestriction patterns, toxin genotype, and MICs of clindamycin, metronidazole, vancomycin, moxifloxacin, ciprofloxacin,
and amoxicillin-clavulanic acid of 37 isolates of C. difficile recovered from patients with antibiotic-associated diarrhea in a Costa Rican hospital
Toxin genotype SmaI pattern
Range of MICs (g ml1)
Clindamycin Metronidazole Vancomycin Moxifloxacin Ciprofloxacin Amoxicillin/clavulanic acid
tcdA tcdB cdtB tcdC with
deletion
001 (NAP1, n  20) 2–256 0.5–4 0.5–1.5 32 32 0.38–1.5
tcdA tcdB tcdC with 447 (n  6) 256 0.09–0.38 0.5–4 32 32 0.75–1
deletion 448 (n  5) 256 0.09–0.75 1–2 32 32 0.75–1
449 (n  1) 256 0.38 4 32 32 1
452 (n  1) 256 0.38 4 32 32 0.75
tcdA tcdB tcdC without 100 (n  1) 12 0.19 0.75 NDa 32 0.38
deletion 247 (NAP9, n  1) 256 0.75 1.5 32 32 1.5
450 (n  1) 256 0.5 0.75 ND 32 0.19
451 (NAP2, n  1) 16 0.25 1 2 32 0.38
a ND, not determined.
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